NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
← catalyst calendarSponsored by Nkarta, Inc. (industry) · NKTX — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
61actual
Sites
8
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-09-21 | actual | When the study began enrolling |
| Primary completion | 2024-10-02 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2039 | estimated | The whole study's end, after follow-up |
| First posted | 2020-11-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-12-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Relapsed/Refractory AML
- AML, Adult
- MDS
- Refractory Myelodysplastic Syndromes
Intervention
- Biological: NKX101 - CAR NK cell therapy — also filed as Cyclophosphamide, Fludarabine, Cytarabine (ara-C), Decitabine
Primary outcomes
what the primary-completion date above is the date OFIncidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
measured 30 days after last dose of NKX101
Response rate to NKX101 (for Part 2)
measured 28 days from first dose of NKX101
Permalink · NKTX's whole pipeline · Catalyst calendar · Every registered study · What changed